Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia -

Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
Information type: Randomised controlled trials
Source: Journal of Clinical Oncology
Specialities: Cancers | Haematological disorders
Summary
RCT (n=299) found no difference between complete remission rates for idarubicin 12mg/m2/d for 3 days vs daunorubicin 90mg/m2/d for 3 days (80.5% vs 74.7% p=0.224). Survival and relapse rates also did not differ.
UKMi comment
In patients with FLT3 internal tandem duplication mutation the median overall survival was superior for daunorubicin (15.5 months vs not reached, p=0.03).
Related links: